The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | How single-cell technologies are reshaping lymphoma immunotherapy
Sandrine Roulland, PharmD, PhD, Center for Immunology of Marseille-Luminy (CIML), Marseille, France, discusses how single-cell and spatial analyses are advancing understanding of the lymphoma tumour microenvironment. She highlights the identification of cellular ecosystems that may predict response to immunotherapy and explains how integrating these technologies into clinical trials could support future AI-driven pathology tools and more personalised treatment strategies. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
